NCT01684865View on ClinicalTrials.gov

An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma

CompletedOBSERVATIONAL
Enrollment

22

Participants

Timeline

Start Date

October 22, 2012

Primary Completion Date

November 27, 2017

Study Completion Date

November 27, 2017

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Rituximab

Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.

Trial Locations (1)

1000

University Clinic of Hematology Skopje, Hospital Care Department, Skopje

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01684865 - An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter